The role of protons in modern and biologically-guided radiotherapy

被引:14
|
作者
Nystrom, Hakan [1 ,2 ]
机构
[1] Skandion Clin, S-75136 Uppsala, Sweden
[2] Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark
关键词
CELL LUNG-CANCER; TUMOR-CONTROL PROBABILITY; NORMAL TISSUE; CONCURRENT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; IMRT TREATMENT; PHASE-II; RISK; DISTRIBUTIONS; OPTIMIZATION;
D O I
10.3109/0284186X.2010.498436
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the introduction of new biologically based imaging possibilities, a higher degree of individualisation and adaptation of radiotherapy will be possible. Better knowledge of the biology of the target and its sub-volumes will enable dose prescriptions tailored to the individual patients, tissues and sub-volumes. Repeated imaging during the course of treatment will in addition enable adaptation of the treatment to cope with anatomical, as well as biological changes of the patient and of the target tissues. To translate these bright future perspectives into significant improvements in clinical outcome, advanced tools to tailor the physical dose distributions are needed. The most conformal radiotherapy technique known to mankind and clinically available today is proton therapy; in particular Intensity Modulated Proton Therapy (IMPT) with active spot scanning can not only tailor the dose to the desired target, but also effectively avoid sensitive structures in the proximity of the target to a degree far better than other conformal techniques such as Intensity Modulated Radiotherapy with photons (IMRT). The development of IMPT is now mature enough for clinical introduction on a broad scale. Proton therapy is still more expensive than conventional radiotherapy, but with the present rapid increase in the number of proton facilities worldwide and new initiatives to improve efficiency, the difference in affordability will continue to decrease and in comparison with the benefits, soon diminish even further. Contrary to what is sometimes claimed, the demands for better physical dose distributions and better avoidance of non-target tissue, has never been higher. Prolonged expected survival in many groups of patients emphasises the need to reduce late toxicities. The success of concomitant systemic therapies, with their tendency to cause higher morbidity stresses even further the increased need for subtle dose-sculpting methodologies and tools. There is no contradiction between striving for better physical dose distributions and a more biologically based approach. On the contrary, physical dose distributions are the tools to which achieve a treatment that can meet the biological demands.
引用
收藏
页码:1124 / 1131
页数:8
相关论文
共 50 条
  • [1] Biologically-guided radiotherapy: a clinical evaluation of automated vs manual planning
    Ureba, Ana
    Oden, Jakob
    Toma-Dasu, Iuliana
    Nicolai, Nils H.
    Ruehle, Alexander
    Baltas, Dimos
    Mix, Michael
    Grosu, Anca L.
    Lazzeroni, Marta
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S3698 - S3701
  • [2] Biologically-guided dose prescription
    Toma-Dasu, I.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S713 - S713
  • [3] Development of the DVH management software for the biologically-guided evaluation of radiotherapy plan
    Kim, BoKyong
    Park, Hee Chul
    Oh, Dongryul
    Shin, Eun Hyuk
    Ahn, Yong Chan
    Kim, Jinsung
    Han, Youngyih
    RADIATION ONCOLOGY JOURNAL, 2012, 30 (01): : 43 - 48
  • [4] Dosimetric Comparison of Biologically-Guided Radiotherapy and X-ray-Guided Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancer
    Hrinivich, W. T.
    Phillips, R.
    Da Silva, A.
    Radwan, N.
    Gorin, M.
    Rowe, S.
    Pienta, K.
    Pomper, M. G.
    Wong, J. W.
    Tran, P. T.
    Wang, K. K. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (05): : 1190 - 1190
  • [5] Biologically-guided treatment - How to plan, deliver and adapt
    Lazzeroni, M.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S713 - S714
  • [6] Development of the DVH management software for the biologically-guided evaluation of radiotherapy plan (vol 30, pg 43, 2012)
    Kim, BoKyong
    Park, Hee Chul
    Oh, Dongryul
    Shin, Eun Hyuk
    Ahn, Yong Chan
    Kim, Jinsung
    Han, Youngyih
    RADIATION ONCOLOGY JOURNAL, 2012, 30 (02): : 97 - 97
  • [7] Biologically-guided isolation of leishmanicidal secondary metabolites from Euphorbia peplus L.
    Amin, Elham
    Moawad, Abeer
    Hassan, Hossam
    SAUDI PHARMACEUTICAL JOURNAL, 2017, 25 (02) : 236 - 240
  • [8] Dose Escalation Strategy for Lung Cancer Patients Using a Biologically-Guided Target Definition
    Shusharina, N.
    Khan, F.
    Choi, N.
    Sharp, G.
    MEDICAL PHYSICS, 2014, 41 (06) : 342 - 342
  • [9] PSMA-Directed Biologically-Guided Radiation Therapy of Castration-Sensitive Oligometastatic Prostate Cancer Patients
    Phillips, R.
    Da Silva, A.
    Radwan, N.
    Gorin, M.
    Rowe, S.
    Deville, C., Jr.
    Song, D.
    Greco, S. C.
    Pienta, K.
    Pomper, M. G.
    DeWeese, T. L.
    Wong, J. W.
    Tran, P. T.
    Wang, K. K. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S152 - S152
  • [10] Understanding Biologically Guided Radiotherapy: Essential Insights for Surgical Oncologists
    Sarma, Gautam
    Medhi, Partha Pratim
    Kashyap, Hrishikesh
    Sharma, Shashi Bhushan
    Kalita, Rupam
    Lahkar, Dhanjit
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024, 15 (SUPPL4) : 599 - 605